2022-10 – Q3 2022 Reporting
Transition to the new Australian based CRO was finalized during Q3.Australian ethical committee has approved increasing dosing period from 3 to 6 months.Reactivation of Australian centers by the new CRO.Centers…
2022-10 – European Patent office has Published a SER150 patent 19th October 2022
European Patent office has Published a SER150 patent 19th October 2022Download
2022-08 – Q2 2022 Reporting
Still low number of patients entered the study in Q2-2022.A new Australian based CRO for SER150 CL-009 clinical study will continue the study on Serodus behalf.Complete transfer expected to be…
2022-05 – Serodus ASA – Notice of postponement
AGM 2022 to be postponed until late june 2022 Read more
2022-05 – Q1 2022 Reporting
Highlights SER150 clinical study in Australia is still delayed after Covid19 lockdownsSerodus received Australian governmental refund (RDTI) for the SER150 Cl-009 study activities.The Group qualified for and received a “Patent…
2021-03 – Announcement Release SER150 CL-009 Approval EC Australia
Announcement Release SER150 CL-009 Approval EC AustraliaDownload
BoD Announcement
Subscription Period to be extended until the 12th of May: Read more
Serodus Prospectus March 2020
Link Serodus Prospectus: Read more